

RESEARCH ARTICLE

Comparison Of Lactobacillus Plantarum, Lactobacillus Mucosae And Lactobacillus Farciminis Bacteria Between Polycystic Ovary Syndrome And Non Polycystic Ovary Syndrome Students At Medical Faculty Of Andalas University

Mentari Faisal Putri,¹ Haviz Yuad,² Andani Eka Putra³

1. Department of Obstetrics and Gynecology, Faculty of Medicine, Andalas University/Dr. M. Djamil Hospital, Padang; 2. Endocrinology and Reproductive Fertility Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Andalas University/Dr. M. Djamil Hospital, Padang; 3. Center for Infectious Disease Diagnostics and Research, Faculty of Medicine, Andalas University/Dr. M. Djamil Hospital, Padang

Correspondence: Mentari Faisal Putri; mentari.faisalputri@qmail.com; 081285483420

Abstract

Background: Polycystic Ovary Syndrome (PCOS) is a disorder characterized by hyperandrogenism, ovulatory dysfunction, and morphological features of polycystic ovaries. It is associated with insulin resistance and hyperinsulinemia. Gut microbial dysbiosis plays a role in PCOS, which is associated with insulin resistance, hyperandrogenism, chronic inflammation, and metabolic syndrome. PCOS treatment with Probiotics maintains the stability and diversity of the gut microbiome.

Objective: To determine the comparison of Lactobacillus plantarum, Lactobacillus mucosae, and Lactobacillus farciminis Bacteria Between Polycystic Ovary Syndrome and Non Polycystic Ovary Syndrome Students at the Medical Faculty of Andalas University.

Method: This research was an analytic observational study using a cross-sectional method conducted on female students with Polycystic Ovary Syndrome and Non-Polycystic Ovary Syndrome at the Medical Faculty of Andalas University.

Results: Bivariate analysis of microbiota comparison of female students with PCOS and without PCOS, Mann-Whitney Test on L.mucosae (p=0.774), while Independent T-Test analysis on L.farciminis (p=0.006).

Conclusion: There is a decrease in microbiota L. Mucosae in female students with PCOS, but there is no significant difference. There is a significant comparison in the number of microbiota L.farciminis in female students with and without PCOS at FK Unand.

Keywords: Polycystic Ovary Syndrome, gut microbiota.



INTRODUCTION

Polycystic ovary syndrome (PCOS) is a disorder characterized by hyperandrogenism, ovulatory dysfunction, and morphological features of polycystic ovaries. World Health Organization (WHO) data shows that approximately 116 million women (3.4%) are affected by PCOS globally. Manifestations of androgen excess (e.g., hirsutism) can cause substantial abnormalities in patients, and polycystic ovary syndrome is the most common cause of anovulatory infertility.¹ Women with PCOS usually have infrequent and irregular periods. Amenorrhea with symptoms of hyperandrogenism (acne, excess facial and body hair, or thinning of scalp hair) is highly suggestive of PCOS.26 Women with endocrine disorders also have higher rates of obesity, dyslipidemia, and insulin resistance. PCOS is associated with insulin resistance and hyperinsulinemia. Obesity and increased waist-hip ratio are commonly found in women with PCOS.^{2,3}

Recent studies have shown that the gut microbiota plays a role in PCOS. Altered microbiota composition (dysbiosis) associated with insulin resistance, hyperandrogenism, chronic inflammation, and metabolic syndrome influences the clinical manifestations of PCOS through short-chain fatty acids, lipopolysaccharides, sex hormones, and the brain-gut axis. With the increasing understanding of gut microbiota in the pathogenesis of PCOS, the use of microbiota-targeted agents (such as probiotics, prebiotics, and synbiotics) in treating PCOS has been discussed recently.⁴

The gut microbiota is an "endocrine organ" that maintains human health and affects the reproductive endocrine system by interacting with estrogens, androgens, insulin, and others. Disorders of gut microbiota are involved in endotoxemia, short-chain fatty acid production, bile acid metabolism, and abnormal secretion of intestinal brain peptides. The above physiological and pathological processes are related to PCOS manifestations such as hyperandrogenism, insulin resistance, chronic inflammatory reactions, and abnormal levels of gut-brain peptides. Therefore, gut microbiota may affect follicular development, sex hormones, and metabolic rate through hyperandrogenism, insulin resistance, chronic inflammation, and brain-gut axis and participate in the pathogenesis of PCOS.⁵

Individual genetic and environmental factors influence the gut microbiome's dynamic and variable microbial community. Sequencing methods have enabled advances in studies on



the gut microbiome. Knowledge of microbiota composition and bacterial gene activity has increased. Probiotic microorganisms are a new perspective of gut microbiota modulation. Lactic acid bacteria (LAB) comprise an important source of probiotics in food products. Due to their beneficial properties, including maintenance of the gut microbiota and disease prevention, LAB is becoming more frequent.⁶ Lactic acid bacteria are referred to as part of the good bacteria. They belong to the normal gut flora and are beneficial for human health. Lactic acid bacteria, particularly rod-shaped lactobacilli, are generally regarded as friendly disposition. They are members of the normal microbial ecosystem in the intestinal tract and play a key role in maintaining the stability and diversity of the gut microbiome.⁷

METHODS

This research was conducted at the Faculty of Medicine, Andalas University, from February to June 2023. The population in this study were all students of the Faculty of Medicine, Andalas University. The sample for this study were all Faculty of Medicine, Andalas University students who met the inclusion criteria, and there were no exclusion criteria. The sample size was determined using the formula for the difference in the means of two independent populations. From the above equation, the minimum number of research subjects in both groups is 19 people.

Stool sampling

Trained enumerators assisted in stool sample collection. Subjects were instructed to contact the enumerator if they were about to defecate. The subjects visited were subjects who contacted the enumerator and defecated around 07.00-15.00 WIB. Feces were put into a sterile tube provided and should not be mixed with urine, toilet water, or other impurities. Feces that are inserted are about 2-5g. The sterile tube was labeled with the code, respondent's name, date, and time of collection. Sterile containers containing stool samples were brought in a coolbox containing ice gel and immediately analyzed at the Microbiology Laboratory of FK Unand.

DNA isolation

Freshly obtained fecal samples were stored at -20°C until the time of use. Then, weigh 200 mg of the stool sample to be analyzed. Suspend in 9 ml Buffer C, then vortex for 20 minutes. Place in a 10 ml injection syringe and filter using a >0.75 μ m filter or sterile cloth.



The liquid is centrifuged at 12,000 rpm for 10 min. The pellet is washed 3 times with Buffer C (1000 μ l/1 ml), vortexed, and then centrifuged at 60 rpm for 5 minutes. The pellet was suspended with 200 μ l lysozyme digestion buffer and vortexed. The procedure was continued according to Promega protocol.

Serial Dilution

Serial dilution is used to make a standard curve, where bacterial culture is done first, followed by suspension with 2 ml PBS, comparison with McFarland scale 1 (3 x 108), DNA isolation, and real-time PCR.

Standard Curve

The standard curve was prepared based on the number of target lactic acid bacteria that were serially diluted. DNA isolation was performed at each dilution stage, and real-time PCR was conducted for each DNA group. The Cq value obtained will be compared with the concentration of bacteria. At the end of this stage, a standard curve will be obtained that can be used to measure the number of bacteria.

Real-Time PCR

Real-Time PCR (Bioline Kit) for its Master Mix composition consists of 10 μ l 2 x SensiFAST Probe No-ROX Mix, 0.8 μ l Foward Primer, 0.8 μ l Reverse Primer, 0.2 μ l Probe, 5 μ l Sample, and 3.2 μ l H2O. The real-time PCR cycle consisted of 1 cycle of Polymerase Activation at 95°C for 2-5 minutes, 40 cycles (Denaturation at 95°C for 10 seconds, Anealling/Extension at 60°C for 20-50 seconds), using the CFX 96 real-time PCR system (Biorad, USA).

RESULT

Characteristics	PCOS (n=21)	Non-PCOS (n=20)	
BMI			
BMI (kg/m²), mean± SD	24,57 ± 6,045	21,55 ± 2,103	
Max (kg/m²)	42,06	26,67	
Min (kg/m²)	17,54	18,29	
Obesity			
Not Obesity (<25 kg/m ²)	14 (66,7%)	19 (95,0%)	
Obesity (\geq 25 kg/m ²)	7 (33,3%)	1 (5,0%)	
Clinical hyperandrogenismism	21 (100%)	5 (25,0%)	
Acanthosis nigricans	6 (28,6%)	1 (5,0%)	

Table 1. Characteristics of Research Respondents

ANDAL eISSN : 25 pISSN : 25

ANDALAS OBSTETRICS AND GYNECOLOGY JOURNAL eISSN : 2579-8324 pISSN : 2579-8323

Based on Table 1, the mean BMI in PCOS students is 24.57 Kg/m² with a standard deviation of 6.045; the highest BMI in PCOS students is 42.06 Kg/m², while the lowest is 17.54 Kg/m². The mean BMI in female students without PCOS was 21.54 Kg/m² with a standard deviation of 2.103. The highest BMI in female students without PCOS was 26.67 Kg/m², while the lowest was 18.28 Kg/m². In female students with PCOS, as many as 7 people (33.3%) were obese, and 14 (66.7%) people were not obese, while there were female students without PCOS obtained as many as 1 person (5.0%) were obese, and 19 people (95.0%) were not obese.

The number of female students with PCOS with clinical hyperandrogenism is 21 people (100%), while the number of female students without PCOS with clinical hyperandrogenism is 5 people (25%). The number of female students with PCOS with acanthosis nigricans is 6 people (28.6%), while the number of female students without PCOS with acanthosis nigricans is 1 person (5.0%).

Microbiota	Variable	N	Mean (Log Cfu/ mL) ±SD	Max (Log Cfu/mL)
Labtobacillus mucosae	PCOS	21	5,66±0,59	7.44
Lactobacillus farciminis	PCOS	21	6,56±0,50	7,48
Labtobacillus mucosae	Not PCOS	20	5,65±0,38	6,43
Lactobacillus farciminis	Not PCOS	20	6,08±0,56	7,24

Table 2. Mean Intestinal Microbiota in PCOS and non-PCOS College Students

Based on Table 2, the average *Lactobacillus mucosae* is 5.66 \pm 0.58 Log Cfu/ml, with the highest number in PCOS female students being 7.44 Log Cfu/ml, the average Lactobacillus facilities is 6.56 \pm 0.50 Log Cfu/ml, with the highest number in PCOS students being 7.48 Log Cfu/ml. The mean *Lactobacillus mucosae* was 5.65 \pm 0.38 Log Cfu/ml, with the highest number in female students without PCOS being 6.43 Log Cfu/mL, the mean *Lactobacillus farciminis* was 6.08 \pm 0.56 Log Cfu/ml, with the highest in female students without PCOS it was 7.24 Log Cfu/mL.



Table 3. Comparison of the number of intestinal microbiota Lactobacillus mucosae and between PCOS and non-PCOS college students

Verieble	Subject		Total n (%)	p-value
Variable	PCOS	Tidak PCOS		
	(n=21)	(n=20)		
Lactobacillus mucosae*	5,43	5,73	41 (100%)	0,419
Lactobacillus farciminis**	6,56±0,50	6,08±0,56	41 (100%)	0,006

*Mann-Whitney Test

**Independent T-Test

The normality test used in this study was the Shapiro-Wilk test because the amount of data in this study was <50 data. The sapphire-will test normality test showed that the data of the variable number of gut microbiota had a normal distribution for Lactobacillus facilities bacteria in female students with and without PCOS with a p-value of 0.089 but an abnormal distribution for *Lactobacillus mucosae* bacteria in female students with PCOS with a p-value of 0.005. The results of the Shapiro-will test normality test became the basis for using the Mann-Whitney Test / Independent T-test bivariate analysis to determine the comparison of the number of intestinal mycobacteria in PCOS and non-PCOS female students. Normally distributed data was conducted by the Independent T-test, while non-normally distributed data was conducted by the Mann-Whitney Test. Independent T-Test bivariate analysis gave a p=0.006 value for *Lactobacillus farciminis*. This shows a significant comparison in this study's number of *Lactobacillus farciminis* of PCOS and non-PCOS female students (Table 3).

Variable	Lactobacillus mucosae (Median)	p-value	
Menstrual cycle			
Normal	5,73	0,419	
Disrupted	5,43		
Clinical Hyperandrogenism			
Yes	5,42	0,076	
No	5,76		
Obesity			
Yes	5,43	0,339	
No	5,71		
Acanthosis nigricans			
Yes	5,44	0,623	
No	5,68		

Table 4. Relationship of Menstrual Cycle Disorder, Clinical Hyperandrogenism, Obesity, and

 Acanthosis nigricans with the number of mucosal Lactobacillus

Based on Table 4, the study results are displayed as medians because the data distribution is abnormal, so they are not displayed as averages. Mann-Whitney Test bivariate analysis showed p values for the relationship of menstrual cycle disorders (p=0.419), clinical hyperandrogenism (p=0.076), obesity (p=0.339), and acanthosis nigricans (p=0.623) with the number of *Lactobacillus mucosae*. This shows that there is no significant relationship between menstrual cycle disorders, clinical hyperandrogenism, obesity, and acanthosis nigricans with the number of *Lactobacillus mucosae* in this study.

Variable	Lactobacillus farciminis	p-value	
Menstrual cycle			
Normal	6,08±0,56	0,006	
Disrupted	6,56 ±0,50		
Clinical Hyperandrogenism			
Yes	6,50±0,52	0,007	
No	6,01±0,56		
Obesity			
Yes	6,64 ±0,50	0,086	
No	6,25±0,57		
Acanthosis nigricans			
Yes	6,56 ±0,49	0,236	
No	6,27±0,59		

Table 5. Relationship between menstrual cycle disorders, clinical hyperandrogenism, obesity,acanthosis nigricans with the number of Lactobacillus farciminis

Based on Table 5, the study results are displayed in the form of averages because the distribution of *Lactobacillus farciminis* data is normally distributed so that an independent t-test can be performed. Bivariate analysis of the independent t-test showed the p-value for the relationship between menstrual cycle disorders (p=0.006) and clinical hyperandrogenism (p=0.007) with the number of *Lactobacillus farciminis*. This indicates that there is a significant relationship between menstrual cycle disorders and clinical hyperandrogenism with the number of *Lactobacillus farciminis* in this study. Bivariate independent t-test analysis showed p values for the association of obesity (p=0.086) and acanthosis nigricans (p=0.236) with the number of *Lactobacillus farciminis*. This indicates no significant relationship between obesity and acanthosis nigricans and the number of *Lactobacillus farciminis* in this study.



DISCUSSION

The study results based on the characteristics of BMI obtained the mean BMI in PCOS students is 24.57 Kg/m², with the highest BMI in PCOS students being 42.06 Kg/m², while the lowest is 17.54 Kg/m². The mean BMI of female students without PCOS is 21.54 Kg/m², with the highest BMI of female students without PCOS being 26.67 Kg/m², while the lowest is 18.28 Kg/m². In female students with PCOS, as many as 7 people (33.3%) were obese, and 14 people were not obese, while there were female students without PCOS, as many as 1 person (5%) was obese, and 19 people (95%) were not obese. A study by Thomas et al. in 2019 found that the majority of women with PCOS (38%-88%) were overweight or obese. This study's data from the Northern Finland Birth Cohort (NFBC) 1966 showed a significant association between body mass index (BMI) and PCOS features at all ages.⁸

The study's results based on clinical hyperandrogenism characteristics showed that the number of female students with PCOS with clinical hyperandrogenism was 20 people (100%). In comparison, the number of female students without PCOS with clinical hyperandrogenism was 5 people (25%). This is explained in a study by Roshan et al. in 2018, that excess adrenal androgens have been reported in 20-30% of women with PCOS, possibly due to defects in cortisol metabolism or biosynthesis of common steroid pathways. This hormone excess in PCOS will give rise to the most common clinical manifestations of hyperandrogenism in women, namely hirsutism and excessive terminal hair growth in androgen-dependent areas of the body. Other clinical manifestations of hyperandrogenism include acne vulgaris, weight gain, menstrual irregularities, and acanthosis nigricans.⁹

The results of the analysis of the mean intestinal microbiota in female students with PCOS obtained the mean of *Lactobacillus mucosae* was 5.66 ± 0.59 Log Cfu/mL with the highest number in PCOS students was 7.44 jml / ml, the mean of *Lactobacillus farciminis* was 6.56 ± 0.50 Log Cfu/mL, with the highest number in PCOS students was 7.48 Log Cfu/mL. Recent studies have revealed that women with PCOS have altered gut flora compared to healthy women. These changes are associated with decreased α -diversity and β -diversity. In addition, many bacterial families, such as Bacteroidaceae, S24-7, Ruminococcaceae, and family Clostridiaceae, were also altered. These findings suggest that gut flora dysbiosis plays a role in the pathogenesis of PCOS.¹⁰

Research by Corrie et al. in 2022 concluded that gut microbiota is critical in influencing human energy metabolism and is strongly associated with PCOS. Some gut bacteria from the genus Lactobacillus, Firmicutes, and Bacteroidetes have a positive association with the development of PCOS. In contrast, some species of Bifidobacterium, most Lactobacillus, and some Bacteroidetes show PCOS-ameliorating effects. Recently, much focus has been placed on understanding the role of the gut microbiota in the pathogenesis of PCOS. Changes in the gut microbiota are known to have positive and negative effects on developing PCOS.¹¹

Mann-Whitney Test analysis obtained a higher median value of *Lactobacillus mucosae* bacteria in female students without PCOS than PCOS. This study's results indicate no significant comparison in the number of *Lactobacillus mucosae* of PCOS and non-PCOS female students. This is to the previous theory of a decrease in non-pathogenic intestinal microbiota such as Bifidobacteria and Lactobacillus; the cell wall of gram-negative pathogenic bacteria contains lipopolysaccharides that can activate the inflammatory response. A diet high in fat, high in sugar, and low in dietary fiber can increase the permeability of the intestinal mucosa. This causes LPS to "leak" from the gut into the circulation (metabolic endotoxemia), triggering an inflammatory response and macrophage activation, leading to insulin resistance and PCOS.¹²

The results of this study are consistent with several studies reviewed in 2016 and 2022. In some of these studies, it has been found a decrease in Lactobacillus, including *Lactobacillus mucosae*, in women with PCOS compared to healthy women. This decrease in Lactobacillus may be associated with an increased risk of PCOS, as it may contribute to the disruption of hormone balance and the development of ovarian cysts.¹³⁻¹⁴ based on research by Guo Y et al. also showed that there was a decrease in lactobacillus bacteria in PCOS compared to not PCOS, where there were significant results associated with gut microbiota dysbiosis in PCOS.¹⁵

Bivariate analysis showed a significant difference in the number of Lactobacillus farciminis in PCOS and non-PCOS female students. However, this study found that lactobacillus was higher in PCOS female students compared to normal female students. Based on the theory of gut microbiota, dysbiosis increases intestinal permeability and can cause chronic low-grade inflammation by activating the immune system. Proinflammatory

cytokines disrupt insulin receptor function, causing IR/hyperinsulinemia, which increases ovarian androgen production, prevents normal follicular development, and causes PCOS.

Proven by research conducted by Yurtdas et al. showed that gut microbiota dysbiosis occurs in PCOS, decreased diversity, and abundance of several species of pathogenic bacteria associated with metabolic disorders. The results of this study are also inconsistent with the study by Gu et al. in 2022, in which there are significant differences between PCOS women and healthy women in both vaginal microbiota and gut microbiota. The results showed a significant decrease in the composition of Lactobacillus in PCOS women. On the other hand, some pathogenic microbiota increased at the same time.¹³ *Lactobacillus mucosae* is a species of lactic acid bacteria that has a mutualistic relationship with humans, assisting in the digestion of food substrates and protection from pathogens by exchanging accommodation and nutrients.

In this study, there were significant results between menstrual cycle disorders and clinical hyperandrogenism with the number of *Lactobacillus farciminis*. However, this study found a higher number of microbiota in female students with PCOS than those without PCOS. This can be influenced by several factors, such as the number of samples, lifestyle, and diagnostic methods used, affecting the results of the average number of bacteria.

Mann Whitney Test bivariate analysis showed no significant relationship between menstrual cycle disorders, clinical hyperandrogenism, obesity, and acanthosis nigricans with the number of *Lactobacillus mucosae* in this study. The results of this study are in line with research conducted by Zhang et al., where at the genus level, it was observed that the abundance of Faecalibacterium, Lachnospira, Bifidobacterium, and Blautia was significantly higher in the control group than in the PCOS group. At the same time, Parabacteroides, Bacteroides, Lactobacillus, Oscillibacter, Escherichia/Shigella, and Clostridium were more abundant in the PCOS group. Research conducted by Torres P et al. also showed no significant difference in obesity between PCOS and non-PCOS patients.^{10,12}

However, this is different from previous theories where Lactobacillus in the gut causes the production of short-chain fatty acids (SCFA) that improve gut health, improve gut barrier function, and reduce the translocation of bacterial endotoxins across the gut wall that can produce inflammation and insulin resistance due to obesity, resulting in excess androgen



production in the ovaries and hyper insulin will increase LH-induced androgen production by teka cells in the ovaries associated with hyperandrogenism and acanthosis nigricans.

These results are in contrast to the results of a study by Crovesy et al. in 2017, which suggests that Lactobacillus strains may play a role in obesity; several studies have investigated the effects of Lactobacillus on body weight and body fat in PCOS and non-PCOS populations. Research using a high-fat diet-induced obese mouse model found that five Lactobacillus strains, including *Lactobacillus farciminis*, decreased body weight and controlled fat accumulation in the body.¹⁶

Bivariate independent t-test analysis showed that menstrual cycle disorders and clinical hyperandrogenism had a significant relationship between menstrual cycle disorders and clinical hyperandrogenism with the number of *Lactobacillus farciminis* in this study. This study is in line with the research of Zhang et al. that increased levels of good bacteria in the gut lead to the production of SCFAs that improve gut health, improve intestinal barrier function, and reduce the translocation of bacterial endotoxins across the intestinal wall, which can cause inflammation and insulin resistance. This is also consistent with the theory that hyperinsulinemia can lead to hyperandrogenism by teka cells in the ovary, causing IR/hyperinsulinemia, which increases ovarian androgen production, prevents normal follicle development, and leads to disruption of the menstrual cycle. In addition, insulin inhibits the production of Sex hormone-binding globulin (SHBG) by the liver, which increases bioavailable testosterone. Excess intraovarian androgens cause anovulation, as excess androgens cause premature luteinization of follicles, which leads to manifestations of menstrual cycle disorders.¹⁷

CONCLUSION

Based on the results of the research Comparison of Lactobacillus plantarum, Lactobacillus mucosae, and Lactobacillus farciminis Bacteria Between Polycystic Ovary Syndrome and Not Polycystic Ovary Syndrome Students at FK Unand, it can be concluded that: characteristics of female students with PCOS as many as 33.3% of students are obese and 28.6% of students have acanthosis nigricans. The mean intestinal microbiota of Lactobacillus mucosae was 5.66 \pm 0.59 Log Cfu/mL. The mean of Lactobacillus farciminis was 6.56 \pm 0.50 Log Cfu/mL in female students with PCOS, while the mean intestinal microbiota of



Lactobacillus mucosae was 5.65 ± 0.38 Log Cfu/mL, and the mean of *Lactobacillus farciminis* was 6.08 ± 0.56 Log Cfu/mL in female students without PCOS at the Faculty of Medicine.

There was a significant difference between the mean number of *Lactobacillus farciminis* in female students with PCOS and female students without PCOS, and there was no significant difference between the mean number of *Lactobacillus mucosae* in female students with PCOS and female students without PCOS at FK Unand. There is a significant relationship between menstrual cycle disorders and hyperandrogenism with the number of Lactobacillus farciminis, and there is no significant relationship between menstrual cycle disorders nigricans with the number of *Lactobacillus mucosae* in female students, hyperandrogenism, obesity, acanthosis nigricans with the number of *Lactobacillus mucosae* in female students at FK Unand.



REFERENCES

- 1. McCartney CR, Marshall JC. Polycystic ovary syndrome. N Engl J Med. 2016;375(1):54–64.
- 2. Dunaif A, Chang RJ, Franks S, Legro RS. Polycystic ovary syndrome: current controversies, from the ovary to the pancreas. Springer Science & Business Media; 2008.
- 3. Taylor HS, Pal L, Sell E. Speroff's clinical gynecologic endocrinology and infertility. Lippincott Williams & Wilkins; 2019.
- 4. Giampaolino P, Foreste V, Di Filippo C, Gallo A, Mercorio A, Serafino P, et al. Microbiome and PCOS: State-of-art and future aspects. Int J Mol Sci. 2021;22(4):1–16.
- Sun Y, Gao S, Ye C, Zhao W. Gut microbiota dysbiosis in polycystic ovary syndrome: Mechanisms of progression and clinical applications. Front Cell Infect Microbiol. 2023;13(February):1–7.
- Aburjaile FF, de Jesus LCL, da Silva TF, Drumond MM, de Oliveira Carvalho RD, Azevedo V, et al. Chapter 12 - Lactic acid bacteria in gut microbiota, probiotics, and disease prevention. In: Ray RC, Paramithiotis S, de Carvalho Azevedo VA, Montet DBTLAB in FB, editors. Applied Biotechnology Reviews. Elsevier; 2022. p. 207–19.
- 7. Berstad A, Raa J, Midtvedt T, Valeur J. Probiotic lactic acid bacteria the fledgling cuckoos of the gut? Microb Ecol Health Dis. 2016;27:31557.
- Barber TM, Hanson P, Weickert MO, Franks S. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clin Med Insights Reprod Heal. 2019;13:117955811987404.
- 9. Dadachanji R, Shaikh N, Mukherjee S. Genetic Variants Associated with Hyperandrogenemia in PCOS Pathophysiology. Genet Res Int. 2018;2018.
- He Y, Wang Q, Li X, Wang G, Zhao J, Zhang H, et al. Lactic acid bacteria alleviate polycystic ovarian syndrome by regulating sex hormone-related gut microbiota. Food Funct. 2020;11(6):5192–204.
- 11. Corrie L, Awasthi A, Kaur J, Vishwas S, Gulati M, Kaur IP, et al. Interplay of Gut Microbiota in Polycystic Ovarian Syndrome: Role of Gut Microbiota, Mechanistic Pathways and Potential Treatment Strategies. Pharmaceuticals. 2023;16(2).
- 12. Yurtdaş G, Akdevelioğlu Y. A New Approach to Polycystic Ovary Syndrome: The Gut Microbiota. J Am Coll Nutr. 2020;39(4):371–82.



- 13. Gu Y, Zhou G, Zhou F, Li Y, Wu Q, He H, et al. Gut and Vaginal Microbiomes in PCOS: Implications for Women's Health. Front Endocrinol (Lausanne). 2022;13(February):1–9.
- 14. Guo Y, Qi Y, Yang X, Zhao L, Wen S, Liu Y, et al. Association between polycystic ovary syndrome and gut microbiota. PLoS One. 2016;11(4):1–15.
- Guo Y, Qi Y, Yang X, Zhao L, Wen S, Liu Y, et al. (2016) Association between Polycystic
 Ovary Syndrome and Gut Microbiota. PLoS ONE 11(4): e0153196.
 doi:10.1371/journal.pone.0153196
- 16. Crovesy L, Ostrowski M, Ferreira DMTP, Rosado EL, Soares-Mota M. Effect of Lactobacillus on body weight and body fat in overweight subjects: A systematic review of randomized controlled clinical trials. Int J Obes [Internet]. 2017;41(11):1607–14. Available from: http://dx.doi.org/10.1038/ijo.2017.161
- 17. El-Bahya AAZ, Radwanb RA, Gadc MZ, Abdel SM. A closer insight into the role of vitamin D in polycystic ovary syndrome (PCOS). Glob J Pharm Pharm Sci. 2018;6(4):79–87.